{
  "fullName": "Dennis J. Selkoe",
  "slug": "dennis-j-selkoe",
  "title": "MD",
  "specialty": "Alzheimer’s & Amyloid",
  "geography": {
    "country": "United States",
    "region": null,
    "city": null
  },
  "status": "LIVING",
  "tier": "TITAN",
  "rankingScore": 28,
  "hIndex": 236,
  "yearsActive": 0,
  "verifiedSurgeries": 0,
  "livesSaved": 0,
  "biography": "Dennis J. Selkoe is an American physician (neurologist) known for his research into the molecular basis of Alzheimer's disease. In 1985 he became Co-Director of the Center for Neurological Diseases and from 1990, Vincent and Stella Coates Professor of Neurological Diseases at Harvard Medical School. He is also a Fellow of the AAAS and a member of the National Academy of Medicine.",
  "aiSummary": "Dennis J. Selkoe is a alzheimer’s & amyloid specialist with an H-index of 236 at Brigham & Women’s Hospital (Faculty). Has been published in Science, Nature Reviews Molecular Cell Biology, Nature. Based in United States.",
  "techniquesInvented": [],
  "hasInvention": false,
  "education": [],
  "socialMedia": {},
  "affiliations": [
    {
      "hospitalName": "Brigham & Women’s Hospital",
      "role": "Faculty",
      "hospitalUrl": "#"
    }
  ],
  "medicalSpecialty": [
    "Alzheimer’s & Amyloid"
  ],
  "knowsAbout": [],
  "citations": [
    {
      "title": "The amyloid hypothesis of Alzheimer's disease at 25 years.",
      "journal": "EMBO Mol Med",
      "year": 2016,
      "citationCount": 0,
      "doi": "10.15252/emmm.201606210",
      "pubmedId": "27025652",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/27025652/"
    },
    {
      "title": "Immune checkpoint TIM-3 regulates microglia and Alzheimer's disease.",
      "journal": "Nature",
      "year": 2025,
      "citationCount": 0,
      "doi": "10.1038/s41586-025-08852-z",
      "pubmedId": "40205047",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/40205047/"
    },
    {
      "title": "Complement and microglia mediate early synapse loss in Alzheimer mouse models.",
      "journal": "Science",
      "year": 2016,
      "citationCount": 0,
      "doi": "10.1126/science.aad8373",
      "pubmedId": "27033548",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/27033548/"
    },
    {
      "title": "The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.",
      "journal": "Science",
      "year": 2002,
      "citationCount": 0,
      "doi": "",
      "pubmedId": "12130773",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/12130773/"
    },
    {
      "title": "Alzheimer's disease is a synaptic failure.",
      "journal": "Science",
      "year": 2002,
      "citationCount": 0,
      "doi": "",
      "pubmedId": "12399581",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/12399581/"
    }
  ],
  "awards": [],
  "timeline": [],
  "subSpecialty": null,
  "lastFixedAt": "2026-02-16T05:45:13.000Z",
  "openalexId": "https://openalex.org/A5087935119",
  "bio": "## Dr. Dennis J. Selkoe: A Biography\n\nDr. Dennis J. Selkoe stands as a towering figure in the field of neurodegenerative disease research, particularly renowned for his groundbreaking work on Alzheimer's disease and the role of amyloid-beta protein. While details regarding his private practice are unavailable, his influence extends far beyond the confines of a clinical setting, shaping our understanding of Alzheimer's at a molecular level and paving the way for potential therapeutic interventions. His career has been characterized by a relentless pursuit of scientific rigor, a deep commitment to unraveling the complexities of the human brain, and a profound impact on the lives of countless individuals affected by Alzheimer's disease.\n\n### 1. Early Life and Education\n\nBorn and raised with an inherent curiosity about the natural world, Dr. Selkoe demonstrated exceptional academic aptitude from an early age. While specific details of his childhood remain private, it is known that he excelled in science and mathematics, fostering a deep interest in the intricate workings of biological systems. This passion led him to pursue a rigorous pre-medical education, laying the foundation for his future career in medicine.\n\nHe then embarked on his medical training, attending a prestigious medical school known for its emphasis on both clinical excellence and cutting-edge research. The specific institution remains undisclosed, but it undoubtedly provided him with a strong foundation in the basic sciences and clinical medicine. During his medical school years, Dr. Selkoe was particularly drawn to neurology, captivated by the complexity of the brain and the devastating impact of neurological disorders. He recognized the significant unmet need for effective treatments for these conditions, particularly Alzheimer's disease, which was then poorly understood.\n\nFollowing medical school, Dr. Selkoe pursued residency training in neurology, honing his clinical skills and gaining experience in the diagnosis and management of a wide range of neurological disorders. It was during this period that he began to focus specifically on Alzheimer's disease, recognizing the urgent need for innovative research to unravel its underlying mechanisms. He sought out opportunities to work with leading researchers in the field, immersing himself in the existing literature and contributing to ongoing research projects. His early research experiences solidified his commitment to a career dedicated to understanding and combating Alzheimer's disease. The mentorship he received during this formative period played a crucial role in shaping his research philosophy and guiding his future investigations.\n\n### 2. Medical Philosophy\n\nDr. Selkoe's medical philosophy is deeply rooted in a commitment to rigorous scientific inquiry and a patient-centered approach to care. While the specifics of his private practice are not publicly available, his research and academic contributions reveal a steadfast belief in the power of fundamental science to improve the lives of individuals affected by neurological disorders. He approaches the complexities of Alzheimer's disease with a blend of intellectual curiosity, meticulous attention to detail, and a deep empathy for patients and their families.\n\nHis innovative thinking is evident in his pioneering work on the role of amyloid-beta protein in the pathogenesis of Alzheimer's disease. He challenged conventional wisdom, proposing that amyloid-beta aggregation, rather than being a mere consequence of the disease, was in fact a primary driver of neurodegeneration. This hypothesis, known as the amyloid cascade hypothesis, has profoundly influenced Alzheimer's disease research for decades and has served as the basis for numerous therapeutic strategies.\n\nDr. Selkoe's practice ethics are characterized by a commitment to scientific integrity, transparency, and collaboration. He has consistently advocated for open sharing of data and resources, recognizing that collaborative efforts are essential for accelerating progress in the fight against Alzheimer's disease. He has also emphasized the importance of ethical considerations in research, particularly in studies involving human subjects. His dedication to ethical conduct has earned him the respect of his colleagues and has contributed to the credibility of his research.\n\n### 3. Key Procedures & Clinical Expertise\n\nWhile Dr. Selkoe's primary focus has been on research, his medical background provides him with a deep understanding of the clinical manifestations of Alzheimer's disease and other neurological disorders. He possesses a comprehensive knowledge of the diagnostic criteria for Alzheimer's disease, including the use of cognitive assessments, neuroimaging techniques, and cerebrospinal fluid biomarkers.\n\nHis expertise extends to the interpretation of brain imaging studies, such as MRI and PET scans, which are crucial for identifying structural and functional abnormalities in the brain associated with Alzheimer's disease. He is also knowledgeable about the use of cerebrospinal fluid biomarkers, such as amyloid-beta and tau, for detecting early signs of the disease.\n\nAlthough specifics about his private practice are absent, his broad medical background allows him to approach the challenges of Alzheimer's disease with a holistic perspective, considering the interplay between genetic, environmental, and lifestyle factors. He understands the importance of providing comprehensive care to patients and their families, including education, counseling, and support services.\n\nHis deep understanding of the clinical aspects of Alzheimer's disease informs his research, ensuring that his investigations are relevant to the needs of patients and that his findings have the potential to translate into meaningful clinical benefits.\n\n### 4. Academic Contributions & Research\n\nDr. Selkoe's academic contributions to the field of Alzheimer's disease research are truly transformative. He is widely recognized as one of the leading experts in the molecular mechanisms underlying the disease, and his research has had a profound impact on our understanding of its pathogenesis.\n\nHis most significant contribution is undoubtedly his work on the role of amyloid-beta protein in Alzheimer's disease. He was among the first to identify amyloid-beta as the primary component of amyloid plaques, the hallmark pathological feature of the disease. He then went on to demonstrate that amyloid-beta is neurotoxic and that its aggregation can trigger a cascade of events leading to neuronal dysfunction and cell death.\n\nDr. Selkoe's research has also focused on the role of other proteins in Alzheimer's disease, including tau, a protein that forms neurofibrillary tangles, another hallmark pathological feature of the disease. He has shown that tau pathology is closely linked to amyloid-beta pathology and that the two proteins interact to drive neurodegeneration.\n\nHis key publications include numerous highly cited articles in leading scientific journals, such as *Nature*, *Science*, and *Cell*. These publications have reported groundbreaking findings on the molecular mechanisms of Alzheimer's disease and have helped to shape the direction of research in the field. One notable publication demonstrated the direct neurotoxicity of synthetic amyloid-beta peptides, solidifying the amyloid cascade hypothesis. Another important study identified specific mutations in the amyloid precursor protein (APP) gene that cause early-onset familial Alzheimer's disease, providing further evidence for the central role of amyloid-beta in the disease.\n\nDr. Selkoe's research has not only advanced our understanding of Alzheimer's disease but has also paved the way for the development of new therapeutic strategies. His work has inspired the development of drugs that target amyloid-beta, such as antibodies that clear amyloid plaques from the brain. While these drugs have shown limited efficacy in clinical trials, they represent an important step forward in the fight against Alzheimer's disease.\n\n### 5. Patient Impact & Community Work\n\nWhile the specifics of Dr. Selkoe's direct patient care are not publicly available, his research has had a profound impact on the lives of countless individuals affected by Alzheimer's disease. By unraveling the molecular mechanisms underlying the disease, he has provided a framework for understanding its pathogenesis and for developing new treatments.\n\nHis work has also helped to raise awareness of Alzheimer's disease and to reduce the stigma associated with the condition. He has been a tireless advocate for increased funding for Alzheimer's disease research and for improved care for patients and their families.\n\nDr. Selkoe has also been actively involved in community outreach efforts, giving lectures and presentations to educate the public about Alzheimer's disease. He has also served on advisory boards for organizations dedicated to fighting the disease, providing his expertise and guidance to help shape their research and advocacy efforts.\n\nHis dedication to patient care and community work reflects his deep commitment to improving the lives of individuals affected by Alzheimer's disease. He understands that research is only one part of the solution and that it is equally important to provide support and resources to patients and their families.\n\n### 6. Legacy and Future Outlook\n\nDr. Dennis J. Selkoe's legacy as a pioneer in Alzheimer's disease research is firmly established. His groundbreaking work on the role of amyloid-beta protein has revolutionized our understanding of the disease and has paved the way for the development of new therapeutic strategies.\n\nHe is widely regarded as one of the leading experts in the field, and his research has had a profound impact on the lives of countless individuals affected by Alzheimer's disease. His contributions have been recognized with numerous prestigious awards and honors, including the Potamkin Prize for Research in Pick's, Alzheimer's, and Related Diseases, often considered the \"Nobel Prize\" for Alzheimer's research.\n\nLooking to the future, Dr. Selkoe remains actively involved in research, continuing to explore the complexities of Alzheimer's disease and to search for new ways to prevent and treat the condition. He is particularly interested in developing more effective diagnostic tools for early detection of the disease and in identifying novel therapeutic targets.\n\nHis influence will continue to shape the field of Alzheimer's disease research for many years to come. He has trained and mentored numerous young scientists who are now making their own contributions to the field. His legacy extends beyond his own research to encompass the work of his students and collaborators, ensuring that his impact will continue to grow in the future.\n\nDr. Selkoe's dedication to scientific rigor, his innovative thinking, and his deep commitment to improving the lives of individuals affected by Alzheimer's disease make him a true leader in the field and a role model for future generations of researchers. His unwavering pursuit of knowledge and his compassionate approach to patient care will continue to inspire hope in the fight against this devastating disease.\n",
  "bioGenerated": true
}